title: Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study.
abstract: OBJECTIVE
  Although platinum based chemotherapy is known to improve the survival duration for the patients with non-small cell lung cancer, the role of platinum for elderly patient is not yet clear. We administered gemcitabine and carboplatin combination therapy to elderly patients with NSCLC. The aim of this study was to evaluate the efficacy and toxicities of this regimen for elderly patients.
  
  
  METHODS
  THE ELIGIBILITY CRITERIA WERE AS FOLLOWS: pathologically confirmed NSCLC, an age >or=65 years, advanced disease with stage IIIB or IV and the patients were chemotherapy-naive. The treatment regimen was as follows; gemcitabine 1,000 mg/m(2) was administered on days 1 and 8 and carboplatin AUC=5 was administered on day 1. This regimen was repeated every 3 weeks. The efficacy was evaluated in terms of the response rate, the time to progression and the overall survival duration.
  
  
  RESULTS
  From Dec 2001 to Feb 2005, a total of 20 patients were entered into this study. The median patient age was 68 years (range: 65 approximately 75). 19 patients were evaluable for their treatment response. A partial response was obtained in 8 patients (response rate: 42.1%, 95% CI: 19.4 approximately 64.8%). The median time to progression and the survival duration were 136 days and 453 days, respectively. Among a total of 65 cycles of treatment, grade 3 or 4 leukopenia and thrombocytopenia were observed in 7.7% and 13.9% of the cycles, respectively. Grade 3 or 4 vomiting was observed in 7.7% of the cycles. Grade 3 skin rash developed in 1.5% of the cycles. 1 patient died of septic shock after chemotherapy.
  
  
  CONCLUSIONS
  Gemcitabine and carboplatin combination chemotherapy was relatively safe and effective for treating elderly patients with NSCLC.
authors.affiliation: Department of Internal Medicine, College of Medicine, Inje University, Sanggye Paik Hospital, Seoul, Korea. yjyuh@paik.ac.kr
authors.forename: Young Jin
authors.initials: YJ
authors.lastname: Yuh
authors.forename: Hyo Rak
authors.initials: HR
authors.lastname: Lee
authors.forename: Sung Rok
authors.initials: SR
authors.lastname: Kim
references.citation: J Thorac Oncol. 2006 Jan;1(1):19-24
references.pmid: 17409822
references.citation: N Engl J Med. 1999 Dec 30;341(27):2061-7
references.pmid: 10615079
references.citation: Ann Oncol. 2000 Oct;11(10):1295-300
references.pmid: 11106119
references.citation: J Clin Oncol. 1990 Sep;8(9):1556-62
references.pmid: 2167953
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: J Clin Oncol. 2005 Nov 20;23(33):8380-8
references.pmid: 16293868
references.citation: Lancet Oncol. 2001 Sep;2(9):533-43
references.pmid: 11905707
references.citation: J Clin Oncol. 2001 Feb 15;19(4):1064-70
references.pmid: 11181670
references.citation: Lung Cancer. 2003 Jul;41(1):81-9
references.pmid: 12826316
references.citation: BMJ. 1995 Oct 7;311(7010):899-909
references.pmid: 7580546
references.citation: J Clin Oncol. 1999 Mar;17(3):921-6
references.pmid: 10071285
references.citation: Cancer. 2000 Jul 15;89(2):328-33
references.pmid: 10918162
references.citation: J Clin Oncol. 1999 Jan;17(1):12-8
references.pmid: 10458212
references.citation: J Clin Oncol. 1999 Jan;17(1):409-22
references.pmid: 10458260
references.citation: Eur J Cancer. 1997 Dec;33(14):2313-4
references.pmid: 9616273
references.citation: J Clin Oncol. 2005 May 1;23(13):3125-37
references.pmid: 15860872
references.citation: J Natl Cancer Inst. 1999 Jan 6;91(1):66-72
references.pmid: 9890172
references.citation: Anticancer Res. 2002 Sep-Oct;22(5):3053-6
references.pmid: 12530041
references.citation: Lung Cancer. 2000 Feb;27(2):75-80
references.pmid: 10688490